BiotechTube
Wilmington PharmaTech

Wilmington PharmaTech

Wilmington, United States· Est.
wilmingtonpharmatech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Wilmington PharmaTech is a private, revenue-generating CDMO focused on complex small molecule and HPAPI chemistry. The company differentiates itself through integrated 'end-to-end' support, combining CRO-like scientific depth with CDMO efficiency, and emphasizes its American manufacturing base for supply chain reliability. With roots from DuPont/Merck and over 20 years of team experience, it has a proven track record, supporting over 200 INDs and multiple commercial products, and is currently undergoing a $50 million expansion to double its US manufacturing capacity.

Drug DeliverySmall Molecules

Technology Platform

Integrated suite of complex chemistry capabilities for small molecules and HPAPIs, including discovery chemistry, solid-state science, process development, analytical services, and GMP manufacturing.

Opportunities

Strong demand for U.S.-based API manufacturing due to supply chain resilience initiatives.
Growth in the HPAPI and complex small molecule market, particularly in oncology.
Expansion of the biotech sector driving outsourcing needs for integrated CDMO services.

Risk Factors

Dependence on client project success and biotech funding cycles.
Execution risk associated with a major $50M capacity expansion.
Intense competition in the small molecule CDMO landscape and regulatory risks inherent to GMP manufacturing.

Competitive Landscape

Operates in the highly competitive small molecule CDMO sector, competing against large global players (e.g., Lonza, Catalent) and other specialized firms. Differentiates through deep complex chemistry/HPAPI expertise, integrated 'end-to-end' services, and a strategic emphasis on U.S.-based manufacturing for supply chain security.

More companies in United States →